Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2026
Impact of urokinase shortage on empyema management and clinical outcomes in Japan.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nishiba Taiki, Yamasaki Daisuke, Ito Shiho, Asai Yusuke, Tanabe Masaki
Аннотация
INTRODUCTION: Urokinase is an important fibrinolytic therapy for empyema. In February 2022, a nationwide shortage occurred, but its impact remains unclear.
PATIENTS AND METHODS: We conducted a retrospective cohort study using a nationwide Japanese administrative database. Adults with empyema who underwent pleural drainage or surgery from January 2020 to December 2023 were identified. Treatment changes were evaluated using interrupted time-series (ITS) analysis and visualized with an alluvial plot. Clinical outcomes were evaluated using multivariable logistic regression. The primary outcome was in-hospital mortality, and the secondary outcome was prolonged hospitalization (≥60 days).
RESULTS: Among 9104 patients, urokinase use declined from 27.1% to 9.2%, whereas surgery increased from 18.9% to 23.0% after February 2022. ITS analysis demonstrated significant post-restriction slope changes in urokinase use (odds ratio [OR] = 0.87, 95% confidence interval [CI] = 0.86-0.88) and surgery (OR = 1.03, 95% CI = 1.01-1.04). The alluvial plot showed reduced urokinase use and increased surgical and conservative management. In-hospital mortality was 13.8% before and 14.5% after the shortage, and the shortage period was not associated with increased in-hospital mortality (adjusted OR: 1.05, 95% CI: 0.92-1.20). No clear increase in prolonged hospitalization was observed.
CONCLUSIONS: The urokinase shortage substantially altered empyema management, although no clear worsening of short-term clinical outcomes was detected.
PATIENTS AND METHODS: We conducted a retrospective cohort study using a nationwide Japanese administrative database. Adults with empyema who underwent pleural drainage or surgery from January 2020 to December 2023 were identified. Treatment changes were evaluated using interrupted time-series (ITS) analysis and visualized with an alluvial plot. Clinical outcomes were evaluated using multivariable logistic regression. The primary outcome was in-hospital mortality, and the secondary outcome was prolonged hospitalization (≥60 days).
RESULTS: Among 9104 patients, urokinase use declined from 27.1% to 9.2%, whereas surgery increased from 18.9% to 23.0% after February 2022. ITS analysis demonstrated significant post-restriction slope changes in urokinase use (odds ratio [OR] = 0.87, 95% confidence interval [CI] = 0.86-0.88) and surgery (OR = 1.03, 95% CI = 1.01-1.04). The alluvial plot showed reduced urokinase use and increased surgical and conservative management. In-hospital mortality was 13.8% before and 14.5% after the shortage, and the shortage period was not associated with increased in-hospital mortality (adjusted OR: 1.05, 95% CI: 0.92-1.20). No clear increase in prolonged hospitalization was observed.
CONCLUSIONS: The urokinase shortage substantially altered empyema management, although no clear worsening of short-term clinical outcomes was detected.